Viridian Therapeutics, Inc.
VRDN
$23.02
-$0.15-0.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.18% | 12.84% | -247.86% | 65.65% | -15.90% |
| Total Depreciation and Amortization | -3.31% | 131.84% | -162.30% | 439.82% | -3.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 260.85% | -58.32% | 61.06% | 3.43% | 17.34% |
| Change in Net Operating Assets | 91.42% | -126.29% | 234.84% | -480.26% | 214.51% |
| Cash from Operations | 11.98% | -403.72% | 71.93% | -12.26% | 18.65% |
| Capital Expenditure | -5,578.26% | 90.42% | -88.98% | -202.38% | 51.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -397.41% | 122.79% | -368.76% | 66.58% | -24.35% |
| Cash from Investing | -399.19% | 122.76% | -369.22% | 66.51% | -24.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,190.34% | -98.16% | 3,024.33% | 1,348.43% | -91.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 15,074.16% | -- | 100.00% |
| Cash from Financing | 5,014.38% | -98.43% | 3,638.68% | 1,321.07% | -91.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.48% | -184.32% | -18.32% | 4,618.03% | -93.33% |